▁has ▁shown ▁the ▁most ▁prom ising ▁results ▁so ▁far . ▁ ▁R TS , S ▁has ▁been ▁fund ed , ▁most ▁recently , ▁by ▁the ▁non - pro fit ▁PATH ▁Mal aria ▁V acc ine ▁In iti ative ▁( M VI ) ▁and ▁Gla x o Smith K line ▁with ▁fund ing ▁from ▁the ▁Bill ▁and ▁Mel inda ▁G ates ▁Foundation . ▁ ▁The ▁R TS , S - based ▁v acc ine ▁form ulation ▁had ▁previously ▁been ▁demonstrated ▁to ▁be ▁safe , ▁well ▁toler ated , ▁imm un ogen ic , ▁and ▁to ▁potentially ▁confer ▁partial ▁effic acy ▁in ▁both ▁mal aria - na ive ▁and ▁- ex per ien ced ▁adult s ▁as ▁well ▁as ▁children . ▁ ▁In ▁November ▁ 2 0 1 2 , ▁find ings ▁from ▁a ▁Ph ase ▁III ▁trial ▁of ▁R TS , S ▁reported ▁that ▁it ▁provided ▁mod est ▁protection ▁against ▁both ▁clin ical ▁and ▁severe ▁mal aria ▁in ▁young ▁inf ants . ▁In ▁October ▁ 2 0 1 3 , ▁Gla x o Smith K line ▁( GS K ) ▁reported ▁that ▁the ▁R TS , S ▁v acc ine ▁reduced ▁the ▁number ▁of ▁cases ▁amongst ▁young ▁children ▁by ▁almost ▁ 5 0 ▁percent ▁and ▁among ▁inf ants ▁by ▁around ▁ 2 5 ▁percent , ▁following ▁the ▁conclusion ▁of ▁an ▁ 1 8 - month ▁clin ical ▁trial . ▁Data ▁showed ▁the ▁protect ive ▁effect ▁after ▁the ▁ 1 8 ▁months , ▁however , ▁was ▁less ▁than ▁had ▁previously ▁been ▁seen ▁after ▁ 1